What is NKTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.16B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NKTX?

P/E (TTM) is n/a and 52-week range is $1.70 to $3.72 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NKTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NKTX?

The company profile lists net income (TTM) near $-113M, EPS (TTM) near $-1.58 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Nkarta Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 71.5M shares outstanding, ISIN US65487U1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Nkarta Inc

$NKTX

Health Care · Biotechnology

IR Run Scenarios

$2.25

+1.35%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 108 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Employees

108

Website

www.nkartatx.com/

IPO

2020-07-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)